Infinitopes has achieved the gold standard among the latest awardees for the Laboratory Efficiency Assessment Framework (LEAF), an innovative initiative to improve laboratory efficiency. As the second BioEscalator tenant to earn this accreditation, they follow in the footsteps of 2023/24 winner, Exogene.
We\u2019re proud to celebrate the graduation of Alethiomics, a University of Oxford spin-out dedicated to developing innovative treatments for blood cancers, as they move from the BioEscalator to their new home at Abingdon Science Park.
Infinitopes received Innovate UK funding through the Investor Partnership Programme, which was pivotal to building and testing their cutting-edge discovery platform, and the Cancer Therapeutics Programme, to design, prepare and execute its phase I clinical trial, that scientists hope will be practice-changing.
U-Ploid Biotechnologies is rewriting the script on fertility treatments, tackling the root cause of age-related egg decline with groundbreaking science.
We are excited to announce that Sandbox Bioscience, an ambitious biotech start-up founded by a team of virology experts from the Oxford ecosystem, has joined the BioEscalator.
U\u2011Ploid, a biotechnology company developing first-in-class therapeutics to address age-related infertility, today announced its selection for the inaugural Merck Corporate Accelerator. The programme, launched by EMD Serono in partnership with the Society for Innovation and Startups (SIS), is designed to support breakthrough innovation in women\u2019s health by providing funding, expert mentorship, and access to Merck\u2019s global network of scientific and clinical leaders.
Infinitopes Ltd today announces that the UK Medicines and Healthcare products RegulatoryAgency (MHRA) has granted Clinical Trial Application (CTA) approval for the first-in-humanPhase I/IIa clinical trial of ITOP1, the company\u2019s lead \u2018off-the-shelf\u2019 cancer vaccine. ITOP1 is a precision cancer vaccine, designed to safely and accurately target tumour antigens, leveraging the company\u2019s vector delivery system, aiming to drive strong and durable T-cell protection for patients with surgically resectable oesophageal adenocarcinoma (OAC).
Care Fertility, a leading fertility treatment provider, and U-Ploid Biotechnologies, a pioneering reproductive health biotech, today announces a research collaboration aimed at improving egg quality and improve fertility treatment. Egg quality is one of the main contributing factors to infertility and is known to deteriorate rapidly with increasing female age. This research collaboration has the potential to validate novel therapeutics and offer hope to millions struggling to conceive.
Dr Vinson brings over 25 years of invaluable experience in the pharma and biotech industry, with a proven track record of leading and contributing to breakthrough therapeutics.
Infinitopes welcomes Jo Brewer, PhD (CSO at Adaptimmune), and Dan Menichella (former CEO and CBO of CureVac's US subsidiary) as incoming Non-Executive Directors, bringing deep expertise in immunotherpay and oncology innovation.
Entelo Bio, a venture backed biotechnology company pioneering the emerging isoform frontier of medicine, releases Flow Agent, an adaptive agentic (autonomous, AI-driven) based workflow management framework for bioinformatics workflows.
Andreas Halner, president and co-founder of Oxford Cancer Analytics (OXcan), chats to TheHill director, Megan Morys-Carter, about the company's inception, what makes the technology so revolutionary and the ever-increasing success OXcan has met with recently.
Scientists in Cambridge have developed a new \u2018super test\u2019 for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate personalised treatment for patients.
U-Ploid, a venture-backed biotechnology company developing next-generation fertility therapeutics, is pleased to announce the appointment of Professor Alison Campbell to its Advisory Board. In this key role, Professor Campbell will provide strategic guidance on company research programmes, working closely with the U-Ploid team to drive innovation in fertility treatments.
TechBio startup, Exogene, is leveraging artificial intelligence (AI) to develop innovative immunotherapies with the potential to eliminate untreatable solid tumours in cancer patients. Through a collaboration with German company Alithea Bio, Exogene hopes to speed up cancer immunotherapy discovery and make it more cost-effective.
Through UK-Germany Collaborative R&D funding, Exogene is collaborating with the German company Alithea Bio, aiming to accelerate cancer immunotherapy discovery and make it more cost-effective.
Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announces that it will be presenting three posters on its pioneering cancer vaccine discovery and development, including one that has been recognised as a \u2018top 100\u2019 poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10th November.
We are excited to welcome Eterna Biologics, a University of Oxford biotech spinout company with a mission to unleash the full potential of RNA medicines. The company aims to enhance global health by expanding the applicability of RNA-targeting medicine to develop treatment for a wide range of human conditions.
![\"A](\"https://www.bioescalator.ox.ac.uk/news-and-events/news/green-is-the-new-gold-infinitopes-awarded-gold-leaf-accreditation/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n